Aurobindo Pharma Subsidiary Terminates US Biosimilar Agreement

🧬 CuraTeQ Biologics, a subsidiary of

, has terminated its licence agreement with US-based BioFactura for the commercialisation of the BFI-751 biosimilar, following a strategic review of its business priorities and portfolio direction.